AtriCure, Inc. (ATRC) is listed on NASDAQ in Medical Device Stocks. It is $48.52, -1.53%, with a $2.5B market cap. RSI is 73.0, overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 73.0 Overbought
Market Cap $2.5B
Volume 155.4K
Fundamentals — 10-Q Q2 2026
Revenue $294.9M
Net Income $9.1M
EPS $0.18
Gross Margin 77.3%
Operating Margin 3.5%
Net Margin 3.1%
Debt / Equity 0.1x
P/E Ratio 269.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Dahlquist Karl S. | Chief Legal Officer | Sell | 9,370 | $48.89 | $458,099 | 2026 Aug 24 |
| Prange Karen | Director | Sell | 3,564 | $38.80 | $138,283 | 2026 Aug 5 |
| Yuen Maggie | Director | Sell | 3,500 | $38.42 | $134,470 | 2026 Aug 5 |
| Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 6,182 | $38.80 | $239,862 | 2026 Jul 29 |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 6,000 | $38.88 | $233,280 | 2026 Jul 28 |
| Wehrwein Sven | Director | Sell | 25,000 | $37.84 | $946,000 | 2026 Jul 28 |
| Prange Karen | Director | Sell | 3,000 | $28.65 | $85,950 | 2026 May 20 |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 5,000 | $28.13 | $140,650 | 2026 May 15 |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 5,000 | $29.83 | $149,150 | 2026 Mar 12 |
| Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 5,166 | $37.29 | $192,640 | 2025 Nov 26 |
| Wehrwein Sven | Director | Sell | 10,000 | $37.66 | $376,578 | 2025 Nov 25 |
| Yuen Maggie | Director | Sell | 3,000 | $35.72 | $107,160 | 2025 Nov 21 |
| Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 3,000 | $36.30 | $108,900 | 2025 Sep 12 |
| Wehrwein Sven | Director | Sell | 5,000 | $37.00 | $185,000 | 2025 Aug 22 |
| Wehrwein Sven | Director | Sell | 5,000 | $36.00 | $180,000 | 2025 Aug 19 |
| Groves Regina E | Director | Sell | 2,452 | $36.82 | $90,283 | 2025 Aug 6 |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 2,500 | $36.58 | $91,450 | 2025 Aug 5 |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 2,500 | $33.44 | $83,600 | 2025 May 28 |
| Prange Karen | Director | Sell | 6,100 | $38.12 | $232,532 | 2025 Mar 5 |
| Yuen Maggie | Director | Sell | 3,500 | $24.07 | $84,245 | 2024 Aug 15 |
Other Medical Device Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $46.83 | 45.9 | $67.9B |
| | $330.77 | 51.3 | $126.9B |
| | $91.21 | 57.7 | $116.7B |
| | $27.14 | 48.2 | $4.4B |
| | $8.44 | 51.9 | $2.2B |
| | $190.31 | 64.7 | $7.3B |
Take ATRC further
- Browse Medical Device Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ATRC in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when AtriCure, Inc. next reports.
Set alerts on ATRC
Get notified when AtriCure, Inc. hits your price targets or technical conditions are met.
Get Started Free